Genetics factors associated with myelodysplastic syndromes

Blood Cells, Molecules, and Diseases

Volumn 55, Issue 1, 2015, Pages 76-81

  Macedo, Luciana Conci ^a   Silvestre, Ana Paula Avenia ^a   Rodrigues, Camila ^a   de Alencar, Josiane Bazzo ^a   Zacarias, Joana Maira Valentini ^a   Ambrosio Albuquerque, Eliane Papa ^a   Sell, Ana Maria ^a   Visentainer, Jeane Eliete Laguila ^a  

^a STATE UNIVERSITY OF MARINGÁ   (Brazil)

Author keywords

Cytogenetic abnormalities; Diagnosis; Epigenetic; Genetics; MDS

Indexed keywords

DNA METHYLTRANSFERASE 3A; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; JANUS KINASE 2; MICRORNA; MICRORNA 125A; MICRORNA 143; MICRORNA 145; MICRORNA 146A; MICRORNA 21; MICRORNA 99B; MICRORNA LET 7E; PROTEIN P53; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; HISTONE DEMETHYLASE; TRANSCRIPTION FACTOR; TUMOR PROTEIN;

ASXL1 GENE; CHROMOSOME 11; CHROMOSOME 12; CHROMOSOME 13; CHROMOSOME 17; CHROMOSOME 20; CHROMOSOME 5; CHROMOSOME 7; CHROMOSOME ABERRATION; CYTOGENETICS; DISEASE CLASSIFICATION; DNA METHYLATION; DNMT3A GENE; EPIGENETICS; EZH2 GENE; GENE; GENE DELETION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC RISK; GENOMIC INSTABILITY; HUMAN; IDH1 GENE; IDH2 GENE; JAK2 GENE; MYELODYSPLASTIC SYNDROME; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RUNX1 GENE; SOMATIC MUTATION; TET2 GENE; TUMOR SUPPRESSOR GENE; UTX GENE; CLASSIFICATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; MUTATION; MYELODYSPLASTIC SYNDROMES; PATHOLOGY; SIGNAL TRANSDUCTION;

CHROMOSOME ABERRATIONS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEMETHYLASES; HUMANS; MICRORNAS; MUTATION; MYELODYSPLASTIC SYNDROMES; NEOPLASM PROTEINS; PHENOTYPE; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84929190275     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2015.04.003     Document Type: Review

References (58)

1. Loken M.R., van de Loosdrecht A., Ogata K., Orfao A., Wells D.A. Flow cytometry in myelodysplastic syndromes: report from a working conference. Leuk. Res. 2008, 32:5-17.
2. Vassallo J., Magalhães S.M.M. Síndromes mielodisplásicas e mielodisplásicas/mieloproliferativas. Rev. Bras. Hematol. Hemoter. 2009, 31:267-272.
3. Barzi A., Sekeres M.A. Myelodysplastic syndromes: a practical approach to diagnosis and treatment. Cleve. Clin. J. Med. 2010, 77:37-44.
4. Sekeres M.A., Schoonen W.M., Kantarjian H., List A., Fryzek J., Paquette R., Maciejewski J.P. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J. Natl. Cancer Inst. 2008, 100:1542-1551.
5. Moraes A.C.R., Licínio M.A., Pagnussat L., Del Moral J.A.G., Santos-Silva M.C. Síndromes mielodisplásicas: aspectos moleculares, laboratoriais ea classificação OMS 2008. Rev. Bras. Hematol. Hemoter. 2009, 31:463-470.
6. Corey S.J., Minden M.D., Barber D.L., Kantarjian H., Wang J.C.Y., Schimmer A.D. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat. Rev. Cancer 2007, 7:118-129.
7. Haferlach T. Molecular genetics in myelodysplastic syndromes. Leuk. Res. 2012, 36:1459-1462.
8. Kawankar N., Vundinti B.Rao Cytogenetic abnormalities in myelodysplastic syndrome: an overview. Hematology 2011, 16:131-138.
9. Owen C., Barnett M., Fitzgibbon J. Familial myelodysplasia and acute myeloid leukaemia-a review. Br. J. Haematol. 2008, 140:123-132.
10. Papaemmanuil E., Gerstung M., Malcovati L., Tauro S., Gundem G., Van Loo P., Yoon C.J., Ellis P., Wedge D.C., Pellagatti A., Shlien A., Groves M.J., Forbes S.A., Raine K., Hinton J., Mudie L.I., McLaren S., Hardy C., Latimer C., Della Porta M.G., O'Meara S S., Ambaglio I., Galli A., Butler A.P., Walldin G., Teague J.W., QuekL L., Sternberg A., Gambacorti-Passerini C., Cross N.C., Green A.R., Boultwood J., Vyas P., Hellstrom.-Lindberg E., Bowen D., Cazzola M., Stratton M.R., Campbell P.J. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013, 122:3616-3627. Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium.
11. Vardiman J. The classification of MDS: from FAB to WHO and beyond. Leuk. Res. 2012, 36:1453-1458.
12. Bernasconi P., Klersy C., Boni M., Cavigliano P.M., Calatroni S., Giardini I., Rocca B., Zappatore R., Caresana M., Dambruoso I. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes. Br. J. Haematol. 2007, 137:193-205.
13. Greenberg P.L., Tuechler H., Schanz J., Sanz G., Garcia-Manero G., Solé F., Bennett J.M., Bowen D., Fenaux P., Dreyfus F., Kantarjian H., Kuendgen A., Levis A., Malcovati L., Cazzola M., Cermak J., Fonatsch C., Le Beau M.M., Slovak M.L., Krieger O., Luebbert M., Maciejewski J., Magalhaes S.M., Miyazaki Y., Pfeilstöcker M., Sekeres M., Sperr W.R., Stauder R., Tauro S., Valent P., Vallespi T., van de Loosdrecht A.A., Germing U., Haase D. Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndrome. Blood 2012, 120:2454-2465.
14. Brunning R.D., Porwit A., Swerdlow S.H. Myelodysplastic syndromes/neoplasms overview. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, 88-93.
15. Raza A., Galili N. The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes. Nat. Rev. Cancer 2012, 12:849-859.
16. West R.R., Stafford D.A., White A.D., Bowen D.T., Padua R.A. Cytogenetic abnormalities in the myelodysplastic syndromes and occupational or environmental exposure. Blood 2000, 95:2093-2097.
17. Abdelrazik H.N., Farawila H.M., Sherif M.A., AlAnsary M. Molecular characterization of chromosome 7 in AML and MDS patients. Afr. J. Health Sci. 2006, 13:33-42.
18. Bejar R., Levine R., Ebert B.L. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J. Clin. Oncol. 2011, 29:504-515.
19. Tefferi A., Vardiman J.W. Myelodysplastic syndromes. N. Engl. J. Med. 2009, 361:1872-1885.
20. Li J. Myelodysplastic syndrome hematopoietic stem cell. Int. J. Cancer 2013, 133:525-533.
21. Arai Y., Yamashita K., Mizugishi K., Takaori-Kondo A., Chiba T., Watanabe T. The implications of myelodysplastic syndrome-associated chromosomal abnormalities in the development of graft-versus-host disease. Eur. J. Haematol. 2013, 90:525-530.
22. Fenaux P., Morel P., Lai J.L. Cytogenetics of myelodysplastic syndromes. Semin. Hematol. 1996, 33:127-138.
23. Asimakopoulos F.A., Green A.R. Deletions of chromosome 20q and the pathogenesis of myeloproliferative disorders. Br. J. Haematol. 1996, 95:219-226.
24. Mhawech P., Saleem A. Myelodysplastic syndrome: review of the cytogenetic and molecular data. Crit. Rev. Oncol. Hematol. 2001, 40:229-238.
25. Pan J., Wu C., Xue Y., Qiu H., Chen S., Zhang J., Bai S., Wu Y., Wang Y., Shen J., Gong Y. The characteristics and prognostic analysis in 213 myeloid malignancy patients with del(20q): a report of a single-center case series. Cancer Genet. 2014, 207:51-56.
26. Bacher U., Haferlach T., Schnittger S., Zenger M., Meggendorfer M., Jeromin S., Roller A., Grossmann V., Krauth M.T., Alpermann T., Kern W., Haferlach C. Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact. Br. J. Haematol. 2014, 164:822-833.
27. Chauffaille M.d.L.L.F. Alterações moleculares em síndrome mielodisplásica. Rev. Bras. Hematol. Hemoter. 2006, 28:188-193.
28. Steensma D.P. The spectrum of molecular aberrations in myelodysplastic syndromes: in the shadow of acute myeloid leukemia. Haematologica 2007, 92:723-727.
29. Mufti G.J., Potter V. Myelodysplastic syndromes: who and when in the course of disease to transplant. ASH Education Program Book 2012, 49-55.
30. Bejar R., Stevenson K., Abdel-Wahab O., Galili N., Nilsson B., Garcia-Manero G., Kantarjian H., Raza A., Levine R.L., Neuberg D. Clinical effect of point mutations in myelodysplastic syndromes. N. Engl. J. Med. 2011, 364:2496-2506.
31. Graubert T., Walter M.J. Genetics of myelodysplastic syndromes: new insights. ASH Education Program Book 2011, 543-549.
32. Delhommeau F., Dupont S., Valle V.D., James C., Trannoy S., Masse A., Kosmider O., Le Couedic J.-P., Robert F., Alberdi A. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 2009, 360:2289-2301.
33. Smith A.E., Mohamedali A.M., Kulasekararaj A., Lim Z., Gäken J., Lea N.C., Przychodzen B., Mian S.A., Nasser E.E., Shooter C. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 2010, 116:3923-3932.
34. Issa J.-P.J. The myelodysplastic syndrome as a prototypical epigenetic disease. Blood 2013, 121:3811-3817.
35. Thol F., Weissinger E.M., Krauter J., Wagner K., Damm F., Wichmann M., Göhring G., Schumann C., Bug G., Ottmann O. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 2010, 95:1668-1674.
36. Gelsi-Boyer V., Trouplin V., Adélaïde J., Bonansea J., Cervera N., Carbuccia N., Lagarde A., Prebet T., Nezri M., Sainty D. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br. J. Haematol. 2009, 145:788-800.
37. Boultwood J., Perry J., Pellagatti A., Fernandez-Mercado M., Fernandez-Santamaria C., Calasanz M.J., Larrayoz M.J., Garcia-Delgado M., Giagounidis A., Malcovati L. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia 2010, 24:1062.
38. Bejar R., Stevenson K., Abdel-Wahab O., Galili N., Nilsson B., Garcia-Manero G., Kantarjian H., Raza A., Levine R.L., Neuberg D., Ebert B.L. Clinical effect of point mutations in myelodysplastic syndromes. N. Engl. J. Med. 2011, 364:2496-2506.
39. Sanada M., Suzuki T., Shih L.-Y., Otsu M., Kato M., Yamazaki S., Tamura A., Honda H., Sakata-Yanagimoto M., Kumano K. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 2009, 460:904-908.
40. Ley T.J., Ding L., Walter M.J., McLellan M.D., Lamprecht T., Larson D.E., Kandoth C., Payton J.E., Baty J., Welch J. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 2010, 363:2424-2433.
41. Lin J., Yao D.-M., Qian J., Chen Q., Qian W., Li Y., Yang J., Wang C.-Z., Chai H.-Y., Qian Z. Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. PLoS One 2011, 6:e26906.
42. Walter M.J., Ding L., Shen D., Shao J., Grillot M., McLellan M., Fulton R., Schmidt H., Kalicki-Veizer J., O'Laughlin M. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011, 25:1153-1158.
43. Damm F., Kosmider O., Gelsi-Boyer V., Renneville A., Carbuccia N., Hidalgo-Curtis C., Della Valle V., Couronné L., Scourzic L., Chesnais V. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood 2012, 119:3211-3218.
44. L'Abbate A., Lo Cunsolo C., Macrì E., Iuzzolino P., Mecucci C., Doglioni C., Coco M., Muscarella L.A., Salati S., Tagliafico E., Minoia C., De Tullio G., Guarini A., Testoni N., Agostinelli C., Storlazzi C.T. FOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalities. BMC Cancer 2014, 14:396.
45. Nikoloski G., Langemeijer S.M.C., Kuiper R.P., Knops R., Massop M., Tönnissen E.R., Van der Heijden A., Scheele T.N., Vandenberghe P., de Witte T. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat. Genet. 2010, 42:665-667.
46. Makishima H., Jankowska A.M., Tiu R.V., Szpurka H., Sugimoto Y., Hu Z., Saunthararajah Y., Guinta K., Keddache M.A., Putnam P. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia 2010, 24:1799.
47. Schapira A.H.V. Mitochondrial diseases. Lancet 2012, 379:1825-1834.
48. Gupta M., Madkaikar M., Rao V.B., Mishra A., Govindaraj P., Thangaraj K., Ghosh K. Mitochondrial DNA variations in myelodysplastic syndrome. Ann. Hematol. 2013, 92:871-876.
49. Quarello P., Garelli E., Brusco A., Carando A., Mancini C., Pappi P., Vinti L., Svahn J., Dianzani I., Ramenghi U. High frequency of ribosomal protein gene deletions in Italian Diamond-Blackfan anemia patients detected by multiplex ligation-dependent probe amplification assay. Haematologica 2012, 97:1813-1817.
50. Vasilatou D., Papageorgiou S.G., Dimitriadis G., Pappa V. Epigenetic alterations and microRNAs: new players in the pathogenesis of myelodysplastic syndromes. Epigenetics 2013, 8:561-570.
51. Starczynowski D.T., Morin R., McPherson A., Lam J., Chari R., Wegrzyn J., Kuchenbauer F., Hirst M., Tohyama K., Humphries R.K., Lam W.L., Marra M., Karsan A. Genome-wide identification of human microRNAs located in leukemia-associated genomic alterations. Blood 2011, 117:595-607.
52. Merkerova M.D., Krejcik Z., Belickova M., Hrustincova A., Klema J., Stara E., Zemanova Z., Michalova K., Cermak J., Jonasova A. Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide. Eur. J. Haematol. 2014, (Epub ahead of print). 10.1111/ejh.12458.
53. Müller-Tidow C., Klein H.-U., Hascher A., Isken F., Tickenbrock L., Thoennissen N., Agrawal-Singh S., Tschanter P., Disselhoff C., Wang Y. Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia. Blood 2010, 116:3564-3571.
54. Khraiwesh B., Arif M.A., Seumel G.I., Ossowski S., Weigel D., Reski R., Frank W. Transcriptional control of gene expression by microRNAs. Cell 2010, 140:111-122.
55. Gañán-Gómez I., Wei Y., Yang H., Pierce S., Bueso-Ramos C., Calin G., Boyano-Adánez M.del C., García-Manero G. Overexpression of miR-125a in myelodysplastic syndrome CD34+ cells modulates NF-κB activation and enhances erythroid differentiation arrest. PLoS One 2014, 9:93404.
56. Yan L.X., Huang X.F., Shao Q., Huang M.Y., Deng L., Wu Q.L., Zeng Y.X., Shao J.Y. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008, 14:2348-2360.
57. Hwang J.H., Voortman J., Giovannetti E., Steinberg S.M., Leon L.G., Kim Y.T., Funel N., Park J.K., Kim M.A., Kang G.H., Kim S.W., Del Chiaro M., Peters G.J., Giaccone G. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One 2010, 5:e10630.
58. Kim Y., Cheong J.W., Kim Y.K., Eom J.I., Jeung H.K., Kim S.J., Hwang D., Kim J.S., Kim H.J., Min Y.H. Serum microRNA-21 as a potential biomarker for response to hypomethylating agents in myelodysplastic syndromes. PLoS One 2014, 4:e86933.